^Higashi Y, Jitsuiki D, Chayama K, Yoshizumi M (2006). „Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, for treatment of cardiovascular diseases”. Recent Patents on Cardiovascular Drug Discovery. 1 (1): 85—93. PMID18221078.
^Yoshida H, Yanai H, Namiki Y, Fukatsu-Sasaki K, Furutani N, Tada N (2006). „Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury”. CNS Drug Reviews. 12 (1): 9—20. PMID16834755. doi:10.1111/j.1527-3458.2006.00009.x.
^Yokoyama H, Takagi S, Watanabe Y, Kato H, Araki T (2008). „Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice”. Journal of Neural Transmission (Vienna, Austria : 1996). 115 (6): 831—42. PMID18235988. doi:10.1007/s00702-008-0019-6.
^Yokoyama H, Yano R, Aoki E, Kato H, Araki T (2008). „Comparative pharmacological study of free radical scavenger, nitric oxide synthase inhibitor, nitric oxide synthase activator and cyclooxygenase inhibitor against MPTP neurotoxicity in mice”. Metabolic Brain Disease. 23 (3): 335—49. PMID18648914. doi:10.1007/s11011-008-9096-3.